Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
MDGL

Madrigal Pharmaceuticals Inc

MDGL

188.81USD-8.49 (-4.30%)Delayed as of 28 Nov 2023, 01:05 pm
Watchlist

Market Summary

USD188.81-8.49
Delayedas of 28 Nov 2023, 01:05 pm
-4.30%

MDGL Alerts

  • 1 major insider buys recently.
  • PAULSON & CO. INC. reported owning 5.1% of MDGL [2023-11-13]

MDGL Stock Price

View Fullscreen

MDGL RSI Chart

MDGL Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

-10.51

Price/Free Cashflow

-12.03

MDGL Price/Sales (Trailing)

MDGL Profitability

Return on Equity

-209.63%

Return on Assets

-94.67%

Free Cashflow Yield

-8.31%

MDGL Fundamentals

MDGL Revenue

MDGL Earnings

Earnings (TTM)

-347.3M

Earnings Y/Y

-21.61%

Earnings Q/Q

-15.08%

Price Action

52 Week Range

57.21322.67
(Low)(High)

Last 7 days

3.8%

Last 30 days

63.9%

Last 90 days

9.9%

Trailing 12 Months

193.8%

How does MDGL drawdown profile look like?

MDGL Financial Health

Current Ratio

3.37

MDGL Investor Care

Shares Dilution (1Y)

8.13%

Diluted EPS (TTM)

-19.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20212.6M1.5M743.0K0
20209.9M8.1M6.1M4.3M
201910.0M11.8M11.8M11.0M
20181.2M2.3M4.9M7.7M
2017000558.0K
20160000
20150000
20140000
20130000
20120000
201112.4M9.9M8.2M7.6M
2010111.9M79.5M47.2M14.8M
2009000144.2M

Latest Insider Trading transactions for MDGL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 21, 2023
baker bros. advisors lp
bought
12,128,300
188
64,350
-
Nov 20, 2023
huntsman carole
acquired
-
-
7,834
chief commercial officer
Nov 20, 2023
baker bros. advisors lp
bought
3,846,580
185
20,709
-
Nov 17, 2023
baker bros. advisors lp
bought
8,100,700
174
46,370
-
Nov 15, 2023
baker bros. advisors lp
bought
2,461,720
161
15,199
-
Nov 14, 2023
baker bros. advisors lp
bought
5,799,650
154
37,660
-
Nov 14, 2023
baker bros. advisors lp
bought
5,347,840
156
34,188
-
Nov 13, 2023
baker bros. advisors lp
bought
10,001,400
143
69,839
-
Sep 11, 2023
sibold william john
acquired
-
-
50,000
president and ceo
Jun 15, 2023
daly james m
acquired
-
-
1,198
-

1–10 of 50

Which funds bought or sold MDGL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
added
18.47
-2,147,240
6,406,920
-%
Nov 22, 2023
Verity Asset Management, Inc.
added
36.67
-61,737
392,409
0.29%
Nov 21, 2023
COMERICA BANK
new
-
4,131
4,131
-%
Nov 16, 2023
McIlrath & Eck, LLC
unchanged
-
-4,418
7,594
-%
Nov 16, 2023
Creative Planning
new
-
302,887
302,887
-%
Nov 15, 2023
Tudor Investment Corp Et Al
added
45.76
-58,369
685,220
0.01%
Nov 15, 2023
Edgestream Partners, L.P.
reduced
-39.03
-364,825
228,845
0.02%
Nov 15, 2023
Dana Investment Advisors, Inc.
new
-
444,984
444,984
0.02%
Nov 15, 2023
Capital Impact Advisors, LLC
unchanged
-
-181,729
312,380
0.52%
Nov 15, 2023
JANE STREET GROUP, LLC
added
157
5,806,980
15,098,500
-%

1–10 of 36

Latest Funds Activity

Are funds buying MDGL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDGL
No. of Funds

Schedule 13G FIlings of Madrigal Pharmaceuticals Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 21, 2023
baker bros. advisors lp
9.99%
1,987,702
SC 13D/A
Nov 13, 2023
paulson & co. inc.
5.1%
-
SC 13G
Oct 10, 2023
janus henderson group plc
15.4%
3,042,661
SC 13G/A
Oct 05, 2023
baker bros. advisors lp
9.99%
2,015,760
SC 13D/A
Sep 08, 2023
janus henderson group plc
10.3%
1,910,301
SC 13G
Aug 08, 2023
baker bros. advisors lp
8.4%
1,545,113
SC 13D/A
Jun 20, 2023
baker bros. advisors lp
8.4%
1,545,113
SC 13D
Feb 14, 2023
baker bros. advisors lp
9.0%
1,545,113
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
9.7%
1,660,000
SC 13G/A
Feb 14, 2023
deep track capital, lp
0%
0
SC 13G/A

Recent SEC filings of Madrigal Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Nov 22, 2023
3
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 21, 2023
4
Insider Trading
Nov 21, 2023
4
Insider Trading
Nov 21, 2023
SC 13D/A
13D - Major Acquisition
Nov 15, 2023
4
Insider Trading
Nov 15, 2023
4
Insider Trading
Nov 13, 2023
SC 13G
Major Ownership Report
Nov 06, 2023
10-Q
Quarterly Report
Nov 06, 2023
8-K
Current Report

Peers (Alternatives to Madrigal Pharmaceuticals Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.8B
-
14.55% 467931.97%
-3.8K
218.4K
- -102.45%
29.6B
10.7B
8.07% -55.95%
-8.54
2.78
-53.67% -129.46%
20.0B
1.7B
4.90% -25.16%
-39.17
11.59
79.37% 56.87%
16.7B
2.3B
9.83% -8.58%
113.5
7.22
15.05% 75.21%
11.8B
3.6B
0.63% -32.44%
27.88
3.28
8.35% -51.49%
MID-CAP
5.7B
272.9M
1.64% -5.18%
-9.43
20.95
141.38% 4.43%
5.2B
-
21.89% 247.20%
-8.88
48.33
54.84% -12.96%
3.6B
631.9M
1.65% 46.39%
-24.37
5.74
23.54% 31.53%
3.1B
223.4M
6.77% 16.65%
-15.53
14.03
- -26.24%
3.1B
256.2M
21.69% -2.64%
-16.98
12
2.51% -17.66%
SMALL-CAP
1.5B
348.4M
17.40% -16.91%
24.23
4.31
81.69% -7.29%
648.3M
1.0B
-14.02% -66.99%
-1.18
0.62
-43.15% 58.48%
108.4M
6.4M
10.81% -79.60%
-0.66
16.83
-44.11% 50.48%
18.7M
-
-19.00% 3569.57%
-0.39
-
- -13.74%
8.0M
-
- -82.21%
-0.12
-
- -29.23%

Madrigal Pharmaceuticals Inc News

Latest updates
Defense World28 Nov 202310:51 am7 hours ago
Defense World28 Nov 202310:04 am8 hours ago
Yahoo Finance27 Nov 202309:30 pm20 hours ago
Boursorama27 Nov 202304:17 pm26 hours ago
Insider Monkey27 Nov 202302:51 pm27 hours ago
InvestorsObserver24 Nov 202304:15 pm4 days ago
Yahoo Finance16 Nov 202308:00 am12 days ago
Nasdaq15 Nov 202308:00 am13 days ago
InvestorsObserver14 Nov 202305:15 pm14 days ago
MyChesCo08 Nov 202308:00 am20 days ago
Yahoo Finance07 Nov 202308:00 am21 days ago
Insider Monkey04 Nov 202304:16 pm24 days ago
Seeking Alpha27 Oct 202307:00 am32 days ago
Seeking Alpha26 Oct 202307:00 am33 days ago
StockNews.com12 Oct 202307:00 am47 days ago

Financials for Madrigal Pharmaceuticals Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q42016Q3
Revenue-34.1%60,00091,000160,000432,000823,0001,204,0001,870,0002,214,0002,766,0003,005,0003,039,0002,979,0002,821,0001,166,000705,000216,000174,00092,00076,00059,00042,000
Operating Expenses2.3%63,160,00061,742,00052,979,00059,555,00058,786,00050,327,00038,005,00029,954,00024,195,00022,704,00018,119,00014,454,00011,333,0007,826,0007,069,0008,911,000-----
  S&GA Expenses-18.0%8,287,00010,110,0007,209,0006,126,0005,494,0005,639,0004,605,0005,044,0004,748,0007,110,0005,746,0005,583,0005,122,0002,717,0001,871,0002,399,000-----
Interest Expenses----------------------
Net Income-2.4%-63,100,000-61,651,000-52,546,000-59,123,000-57,963,000-49,023,000-36,135,000-27,740,000-21,429,000-19,699,000-15,080,000-11,475,000-8,512,000-6,460,000-6,364,000-8,445,000-----
Net Income Margin-107.2%-318-153-83.49-46.72-27.96-16.68-10.65-7.62-5.74------------
Free Cashflow2.7%-45,606,000-46,883,000-43,473,000-54,957,000-47,853,000-24,265,000-30,820,000-12,416,000-------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-21.3%238302332363159216223273305328310287340388411442456470480485490
  Current Assets-21.9%235302331361157215221272303326308285338387409440455469478485489
    Cash Equivalents-19.6%62.0077.0011333259.0053.0042.0036.0049.0034.0044.0054.0010962.0067.0047.0089.0073.0047.0057.0038.00
  Net PPE44.8%1.000.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.000.000.000.000.00
Liabilities8.4%21619918216514813377.0077.0070.0057.0049.0047.0050.0045.0026.0025.0016.0013.0011.008.007.00
  Current Liabilities0.0%10010098.0011699.0084.0077.0077.0069.0057.0049.0047.0049.0045.0026.0025.0015.0012.0010.008.007.00
    LT Debt, Non Current15.6%11599.0084.0049.0049.0049.00---------------
Shareholder's Equity-78.5%22.0010415019711.0084.00146196235271261240290343385417440457469477483
  Retained Earnings-8.8%-1,224-1,125-1,039-962-876-795-724-667-602-539-478-425-366-308-259-223-195-174-154-139-127
  Additional Paid-In Capital1.4%1,2461,2291,1901,160888880871863838810739665656650644640636631623617611
Shares Outstanding0.2%18.0018.0018.0018.0017.0017.0017.0017.0017.0017.0016.0016.0015.0015.0015.0015.0015.0015.0015.0015.0015.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-12.8%-84,920-75,310-84,067-58,515-59,069-57,360-49,913-48,051-45,556-46,881-43,429-54,947-47,850-24,258-30,506-12,282-11,324-11,540-6,478-6,265-5,238
  Share Based Compensation15.4%12,66010,97311,2508,0828,1227,9447,4776,3566,2428,1796,0965,1345,0615,6894,8464,0324,9507,7556,0225,1194,976
Cashflow From Investing1445.1%50,199-3,732-186,86466,38765,13719,23655,92615,64340,091-27,325-33,464-4,79894,75319,36550,460-30,50728,26736,438-3,49124,988-222,028
Cashflow From Financing-54.4%19,58042,93052,690264,337-49,114-19,50321,09963,54167,0944,629350109--35.0011783.00610451

MDGL Income Statement

2023-09-30
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues
Operating expenses:    
Research and development70,95168,271201,710174,699
General and administrative27,58312,14161,61033,573
Total operating expenses98,53480,412263,320208,272
Loss from operations(98,534)(80,412)(263,320)(208,272)
Interest income3,29871710,6251,109
Interest expense(3,504)(1,502)(8,741)(2,282)
Net loss$ (98,740)$ (81,197)$ (261,436)$ (209,445)
Net loss per common share:    
Basic net loss per common share$ (5.34)$ (4.75)$ (14.27)$ (12.25)
Diluted net loss per common share$ (5.34)$ (4.75)$ (14.27)$ (12.25)
Basic weighted average number of common shares outstanding18,476,41417,103,39518,326,15417,103,395
Diluted weighted average number of common shares outstanding18,476,41417,103,39518,326,15417,103,395

MDGL Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 62,055$ 331,549
Marketable securities170,29627,225
Prepaid expenses and other current assets3,1182,595
Total current assets235,469361,369
Property and equipment, net659601
Right-of-use asset1,836602
Total assets237,964362,572
Current liabilities:  
Accounts payable16,54223,831
Accrued expenses82,61091,461
Lease liability513602
Total current liabilities99,665115,894
Long term liabilities:  
Loan payable, net of discount114,72749,289
Lease liability1,323
Total long term liabilities116,05049,289
Total liabilities215,715165,183
Stockholders' equity:  
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at September 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, par value $0.0001 per share authorized: 200,000,000 at September 30, 2023 and December 31, 2022; 18,494,192 and 18,102,523 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively22
Additional paid-in-capital1,246,3851,160,079
Accumulated other comprehensive loss(42)(32)
Accumulated deficit(1,224,096)(962,660)
Total stockholders' equity22,249197,389
Total liabilities and stockholders' equity$ 237,964$ 362,572
MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
 WEBSITEwww.madrigalpharma.com
 EMPLOYEES92

Madrigal Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Madrigal Pharmaceuticals Inc?

Ticker symbol for Madrigal Pharmaceuticals Inc is MDGL.

What is the market capital of Madrigal Pharmaceuticals Inc (MDGL)?

As of Mon Nov 27 2023, market cap of Madrigal Pharmaceuticals Inc is 3.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart. The fair value of Madrigal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Madrigal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDGL so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Madrigal Pharmaceuticals Inc stock overpriced or underpriced?

The fair value guage provides a quick view whether MDGL is over valued or under valued. Whether Madrigal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Madrigal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDGL.